Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitrofurantoin is a nitrofuran antibiotic used primarily to treat uncomplicated urinary tract infections. It works by being rapidly reduced inside bacterial cells by flavoproteins (nitrofuran reductase) to multiple reactive intermediates that damage bacterial DNA and attack ribosomal proteins, respiration pathways, pyruvate metabolism, and other macromolecules. This multi-targeted mechanism inhibits several biochemical and synthetic processes in the bacterial cell and contributes to its low rate of acquired resistance. Nitrofurantoin is concentrated in the urine after oral administration, making it especially effective for lower urinary tract infections but not for kidney infections[1][5][6][8]. The drug was first approved in 1953.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nitrofurantoin.